Home Blood / Hematology Dr. Castillo on the Use of Venetoclax in Waldenstrom Macroglobulinemia

Dr. Castillo on the Use of Venetoclax in Waldenstrom Macroglobulinemia

95
0

Jorge J. Castillo, MD, clinical director, Bing Center for Waldenström Macroglobulinemia, physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of a multicenter, prospective, phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia.

<<< 17th International Myeloma Workshop

This site uses Akismet to reduce spam. Learn how your comment data is processed.